IFNα Potentiates Immune-Checkpoint Blockade by Rewiring Metabolic Cross-talk

In this issue, Hu and colleagues unveil that IFN alpha administration combined with anti-PD-1 therapy can potentiate murine and human CD8(+) T-cell antitumor response in hepatocellular carcinoma, highlighting a novel therapeutic strategy for hepatocellular carcinoma.

Automated summary

Hu and colleagues demonstrate that the combination of IFN alpha administration and anti-PD-1 therapy can enhance the antitumor response of CD8(+) T-cells in hepatocellular carcinoma, suggesting a novel therapeutic strategy.